ABIVAX Société Anonyme (EPA:ABVX)
France · Delayed Price · Currency is EUR | Market Cap | 3.45B |
| Revenue (ttm) | 10.59M |
| Net Income (ttm) | -185.75M |
| Shares Out | 63.47M |
| EPS (ttm) | -2.94 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,416,436 |
| Average Volume | 304,677 |
| Open | 42.60 |
| Previous Close | 8.90 |
| Day's Range | 42.00 - 58.30 |
| 52-Week Range | 4.51 - 58.30 |
| Beta | 1.53 |
| RSI | 98.53 |
| Earnings Date | Aug 11, 2025 |
About ABIVAX Société Anonyme
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod that is in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis, as well as in Phase 2b clinical trial to treat patients with Crohn’s disease. The company was incorporated in 2013 and is headquartered in Paris, France. [Read more]
Financial Performance
In 2024, ABIVAX Société Anonyme's revenue was 10.79 million, an increase of 135.94% compared to the previous year's 4.57 million. Losses were -176.24 million, 19.3% more than in 2023.
Financial StatementsNews
Abivax launches $400M U.S. public offering of ADSs
Abivax Announces Launch of Public Offering
Abivax Announces Launch of Public Offering PARIS, France, July 23, 2025 – 10:15 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnolog...
Abivax: Differentiated Phase 3 Data Ignites A Multi-Billion Dollar Opportunity
Crude Oil Falls; Thermo Fisher Scientific Earnings Top Views
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 350 points on Wednesday. The Dow traded up 0.82% to 44,869.16 while the NASDAQ rose 0.16% to 20,925.86. The...
GE Vernova Posts Better-Than-Expected Earnings, Joins Thermo Fisher Scientific, Lennox International, General Dynamics And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were higher, with the Dow Jones index gaining around 200 points on Wednesday. Shares of GE Vernova Inc . (NYSE: GEV) rose sharply during Wednesday's session after the company posted bette...
Abivax Hits The Stratosphere, Up 500%, On 'Potentially Disruptive' Results
Shares of Abivax hit the stratosphere Wednesday after the firm unveiled "potentially disruptive" results for its ulcerative colitis drug.
Abivax Stock Skyrockets On Strong Data From Inflammatory Bowel Disorder Study
Abivax shares jump as obefazimod meets key ... Full story available on Benzinga.com
Abivax skyrockets 400% as late-stage trial for lead asset succeeds in ulcerative colitis
Abivax: Good Entry Point Ahead Of The Mega Catalyst - Phase 3 Data Readout
Abivax Announces Results of its June 6, 2025 Annual General Meeting
Abivax Announces Results of its June 6, 2025 Annual General Meeting PARIS, France, June 11, 2025, 10:00 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX) (“Abivax” or the “Co...
Abivax reports Q1 results
Abivax Presents First Quarter 2025 Financial Results
Abivax Presents First Quarter 2025 Financial Results PARIS, France, June 2, 2025, 10:00 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX) (“Abivax” or the “Company”), a clini...
Biotech Bull Case, ABVX International Interest, JNJ & LLY Options Trades
"You cannot not believe in science," says Tsvetta Kaleynska. She sees biotech companies outperforming in 2025 despite a slow start to the year.
Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis
Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis
Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones
Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones Annual General Meeting scheduled for Friday, June 6, 2025, in Paris, France Phase 3 ABTECT ...
Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors
Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors Industry veteran brings deep immunology expertise ahead of key Phase 3 data readout in ulcerative colitis expected in Q3 2025 P...
ABIVAX: Undercovered, Late-Stage French Company With Upcoming Catalysts
Abivax publishes financial reports with the French and U.S. securities regulatory agencies
Abivax publishes financial reports with the French and U.S. securities regulatory agencies PARIS, France – March 26, 2025 – 10:05 PM CET – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “C...
Abivax reports FY results
Abivax reports FY net financial loss of EUR -3.3M, with operating income rising to EUR 12.5M in 2024 from EUR 4.6M in 2023.
Abivax Announces Full Year 2024 Financial Results
Abivax Announces Full Year 2024 Financial Results • Cash balance of EUR 144.2M as of December 31, 2024; cash runway into Q4 2025 Full enrollment in Phase 3 ABTECT trial evaluating obefazimod fo...
Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025
Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025 Event to Feature Renowned Gastroenterologist Dr. David Rubin, Highlighting the Ulcerative Colitis Treatment Landscape and Abivax's Piv...
Abivax Publishes 2025 Financial Calendar
Abivax Publishes 2025 Financial Calendar PARIS, France – January 28, 2025 – 8:30 AM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage b...
Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn's and Colitis Organization 20th Annual Congress
Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn's and Colitis Organization 20th Annual Congress
Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment
Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment Phase 3 ABTECT Trial evaluating obefazimod for moderately to severely active ulcerative colitis (“UC”) reaches 1,003 of 1,224 participa...
Abivax Announces a Change to the Composition of its Board of Directors
Abivax Announces a Change to the Composition of its Board of Directors PARIS, France, December 23, 2024, 10:05 PM CEST – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinic...